Abstract. Chagas' disease, which is caused by Trypanosoma cruzi, remains essentially incurable. Due principally to a lack of profit incentive, the pharmaceutical industry has had limited interest in developing new antichagasic drugs. Thus, a search for agents that exhibit activity against T. cruzi, although medicaments have been developed for the treatment of other diseases, seems justifiable. Responding to evidence that the principal biochemical differences between mammalian cells and African trypanosomes apply equally to T. cruzi, our evaluations were conducted. Previous work showed the effectiveness of anticancer agents against T. rhodesiense. In the present studies, 76 anticancer compounds were assessed for their ability to suppress the trypomastigotes of T. cruzi-infected mice. Five compounds were found to be active. The most effective was cycloheximide, which was more than six times as effective as the standard, nifurtimox.
† Nifurtimox was used as a reference drug for the N index. N index ϭ suppressive dose (SD) for nifurtimox/SD for test compound ϫ 1/[(1 Ϫ formula weight due to salt)/(total formula weight)]. Bracketing dosages (milligrams/kilogram/day for four days): Reference compound, 200-50; compound no. 1, 100-6.25; compound nos. 2-5, 400-50.
‡ Number assigned by the Walter Reed Army Institute of Research. § Number assigned by the Drug Synthesis and Chemistry Branch, Developmental Therapeutic Program, National Cancer Institute.
¶ TRI ϭ compounds found to be inactive against T. brucei rhodesiense infections previously reported. 3, 4 # TRA ϭ compounds found to be active against T. brucei rhodesiense infections previously reported. 3, 4 *
It has been reported that most of the principal biochemical differences between mammalian cells and African trypanosomes apply equally to Trypanosoma cruzi, the organism that causes Chagas' disease. 1, 2 Thus, compounds effective against the former may be active against the latter. Kinnamon and others have previously reported that certain anticancer agents are suppressive in T. rhodesiense-infected mice. 3, 4 In an attempt to identify compounds that are curative for the American trypanosome, T. cruzi, 76 compounds identified by the National Cancer Institute as having anticancer activity were provided to us and tested.
MATERIALS AND METHODS
Animal model and procedures. The system used was as described elsewhere 5 and was designed to determine the suppressive activity of test compounds against trypomastigotes of T. cruzi in the blood of infected mice. More specifically, female albino mice (four to six weeks old, CF 1 strain; Harlan-Sprague Dawley, Madison, WI) and a Brazil strain of T. cruzi were used. 6 The organism was maintained by passage every two weeks in 4-6-week-old mice. Blood was drawn into a heparinized syringe from a donor mouse by cardiac puncture. The appropriate dilution was then prepared in Hanks' balanced salt solution, pH 7.2, and 0.2 ml of this suspension containing 50,000 trypomastigotes was injected intraperitoneally into each test mouse. Twice daily oral administration of the experimental compound was begun on day 11 of the infection and continued through day 14. Each compound was suspended in a 0.1% Tween 80 plus 0.5% hydroxyethylcellulose (HEC-Tween). Drug dosage levels ranged from 0.8125 to 104 mg/kg/day using six animals at each dose level. Control groups consisted of mice receiving vehicle only (negative controls) and others receiving nifurtimox (positive controls). Blood smears were prepared on day 15 and numbers of parasites/ml of blood were determined.
The experiments reported herein were conducted according to principles set forth in the Animal Welfare Act as amended and its promulgated regulations (7 USC, para. Handling of data. A comparison of the antischizotrypanosomal activity of each test compound with that of the ref-
, was made and an index (relative activity of the test compound with that of nifurtimox for each test compound) was calculated by the following formula: nifurtimox index (NI) ϭ SD 50 for nifurtimox Ϭ SD 50 for the test compound, where SD represents the amount of compound (mg/kg) that produced a specified degree (50%) of suppression of the infection. Since the compounds were tested blind, each was administered on the basis of total compound weight, unadjusted for formula weight due to the acid component in salts.
Final correction was made in salts by taking into consideration the acid combined with the base. This was done by multiplying the index obtained by the reciprocal of the fraction of base component in the salt. § TRI ϭ compounds found to be inactive against T. brucei rhodesiense infections previously reported. 3, 4 ¶ TRA ϭ compounds found to be active against T. brucei rhodesiense infections previously reported. 3, 4 The degree of suppression (e.g., SD 50 ) was estimated graphically from plots of percent parasite suppression and dose of compound administered (mg/kg/day) on log probit paper. When the SD 50 could not be obtained because of low activity of the test compound, a lower SD value was used. A nifurtimox index of greater than one indicates that the test compound is more active than the reference compound. Data for compounds that were found to be active are shown in Table 1 . Those that were found not to be active are listed in Table 2 . Of the five compounds found to be suppressive, cycloheximide was most effective, having activity 6.6 times that of the reference drug nifurtimox. DISCUSSION Cycloheximide (no. 1 in Table 1 ), the antibiotic substance isolated from the beers (liquid products after fermentation) of streptomycin-producing strains of Streptomyces griseus, is a potent inhibitor of protein synthesis. Exactly how this inhibition works is not known. Although cycloheximide was found in the present work to have significant in vivo activity 6.6 times more effective than the standard, others using in vitro means found it to be inactive against T. cruzi. 7 These investigators and others also using in vitro methods found the following not to be effective in their T. cruzi systems: reserpine, 8 cisplatin, 8 cyclophosphamide, 8, 9 cytosine arabinoside, 7 ellipticine, 7 5-fluorouracil, 7 hydroxyurea, 7 melphalan, 7, 8 mercaptopurine, 7 and methotrexate. 7, 8 The assumption that the principal biochemical differences between mammalian cells and both American and African trypanosomes are largely the same 1, 2 bears examination. When comparing results when using the test model for T. cruzi described herein and the data reported previously for T. rhodesiense, 3, 4 one finds a decided difference in response to the anticancer compounds used (Table 3) . Using McNemar's (continuity correction) test, the difference in activity rates between the American (5 of 75 ϭ 6.6%) and the African (17 of 76 ϭ 22.4%) trypanosomes was statistically significant (McNemar's 2 ϭ 6.72; 2P ϭ 0.0095). 9 When addressing the value of anticancer compounds, more generally, and cycloheximide, specifically as antichagasic agents, one must consider general cellular toxicity. However, there is toxicity to the host with essentially all therapeutic agents. The issue is the therapeutic index. Our armamentarium of drugs to treat T. cruzi is sorely lacking. Although nifurtimox and benznidazole are used in Latin American countries, 10, 11 they and a few others have only limited utility. The disease remains essentially incurable. Due principally to lack of a profit incentive, the pharmaceutical industry has had limited interest in the development of new antichagasic drugs. 12, 13 Thus, the search for agents that exhibit activity against T. cruzi, although medicaments have been developed for the treatment of other diseases, has been encouraged. 12 Finding a compound such as cycloheximide that has clinical activity against T. cruzi more than six times that of nifurtimox, even with its known shortcomings, would represent a significant stride forward. Perhaps examining others members in the spectrum of anticancer drugs is worthy of pursuit.
